VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.

Michaelsen, Signe R; Staberg, Mikkel; Pedersen, Henriette; Jensen, Kamilla E; Majewski, Wiktor; Broholm, Helle; Nedergaard, Mette K; Meulengracht, Christopher; Urup, Thomas; Villingshøj, Mette; Lukacova, Slávka; Skjøth-Rasmussen, Jane; Brennum, Jannick; Kjær, Andreas; Lassen, Ulrik; Stockhausen, Marie-Thérése; Poulsen, Hans S; Hamerlik, Petra

Michaelsen, Signe R; Staberg, Mikkel; Pedersen, Henriette; Jensen, Kamilla E; Majewski, Wiktor; Broholm, Helle; Nedergaard, Mette K; Meulengracht, Christopher; Urup, Thomas; Villingshøj, Mette; Lukacova, Slávka; Skjøth-Rasmussen, Jane; Brennum, Jannick; Kjær, Andreas; Lassen, Ulrik; Stockhausen, Marie-Thérése; Poulsen, Hans S; Hamerlik, Petra.

Afiliação

Michaelsen SR; Department of Radiation Biology, Copenhagen University Hospital, Copenhagen, Denmark.
Staberg M; Danish Cancer Society Research Center, Copenhagen, Denmark.
Pedersen H; Department of Radiation Biology, Copenhagen University Hospital, Copenhagen, Denmark.
Jensen KE; Danish Cancer Society Research Center, Copenhagen, Denmark.
Majewski W; Danish Cancer Society Research Center, Copenhagen, Denmark.
Broholm H; Danish Cancer Society Research Center, Copenhagen, Denmark.
Nedergaard MK; Center for Genomic Medicine, Copenhagen University Hospital, Copenhagen, Denmark.
Meulengracht C; Department of Neuropathology, Center of Diagnostic Investigation, Copenhagen University Hospital, Copenhagen, Denmark.
Urup T; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Copenhagen University Hospital, Copenhagen, Denmark.
Villingshøj M; Danish Cancer Society Research Center, Copenhagen, Denmark.
Lukacova S; Department of Radiation Biology, Copenhagen University Hospital, Copenhagen, Denmark.
Skjøth-Rasmussen J; Department of Radiation Biology, Copenhagen University Hospital, Copenhagen, Denmark.
Brennum J; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Kjær A; Department of Neurosurgery, Copenhagen University Hospital, Copenhagen, Denmark.
Lassen U; Department of Neurosurgery, Copenhagen University Hospital, Copenhagen, Denmark.
Stockhausen MT; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Copenhagen University Hospital, Copenhagen, Denmark.
Poulsen HS; Department of Radiation Biology, Copenhagen University Hospital, Copenhagen, Denmark.
Hamerlik P; Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark.

Neuro Oncol ; 20(11): 1462-1474, 2018 10 09.

Article em En | MEDLINE | ID: mdl-29939339

Assuntos

Bevacizumab/farmacologia; Glioblastoma/patologia; Fator C de Crescimento do Endotélio Vascular/metabolismo; Receptor 2 de Fatores de Crescimento do Endotélio Vascular/metabolismo; Inibidores da Angiogênese/farmacologia; Animais; Apoptose; Comunicação Autócrina; Biomarcadores Tumorais/genética; Biomarcadores Tumorais/metabolismo; Ciclo Celular; Proliferação de Células; Feminino; Regulação Neoplásica da Expressão Gênica; Glioblastoma/tratamento farmacológico; Glioblastoma/metabolismo; Humanos; Camundongos; Camundongos Nus; Transdução de Sinais; Células Tumorais Cultivadas; Fator C de Crescimento do Endotélio Vascular/genética; Receptor 2 de Fatores de Crescimento do Endotélio Vascular/genética; Ensaios Antitumorais Modelo de Xenoenxerto

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Glioblastoma / Receptor 2 de Fatores de Crescimento do Endotélio Vascular / Fator C de Crescimento do Endotélio Vascular / Bevacizumab Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google